EdgarLookup

Vertiv Holdings Co — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Vertiv Holdings Co filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
10.9%
Return on Assets
Net income ÷ assets
2.1x
Debt-to-Equity
Total liabilities ÷ equity

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2019 Dec 31, 2019 $0 Mar 12, 2020
FY2019 Dec 31, 2018 $0 Mar 12, 2020
FY2019 Dec 31, 2017 $0 Mar 12, 2020
FY2018 Dec 31, 2016 $0 Mar 13, 2019

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $10.23B Feb 13, 2026
FY2025 Dec 31, 2024 $8.01B Feb 13, 2026
FY2025 Dec 31, 2023 $6.86B Feb 13, 2026
FY2024 Dec 31, 2022 $5.69B Feb 18, 2025
FY2023 Dec 31, 2021 $5.00B Feb 23, 2024
FY2020 Dec 31, 2020 $1.31B Apr 30, 2021
FY2020 Sep 30, 2020 $1.16B Apr 30, 2021
FY2020 Jun 30, 2020 $1.01B Apr 30, 2021
FY2020 Mar 31, 2020 $897.30M Apr 30, 2021
FY2020 Dec 31, 2019 $1.17B Apr 30, 2021

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.33B Feb 13, 2026
FY2025 Dec 31, 2024 $495.80M Feb 13, 2026
FY2025 Dec 31, 2023 $460.20M Feb 13, 2026
FY2024 Dec 31, 2022 $76.60M Feb 18, 2025
FY2023 Dec 31, 2021 $119.60M Feb 23, 2024
FY2020 Dec 31, 2020 $40.50M Apr 30, 2021
FY2020 Sep 30, 2020 ($103.50M) Apr 30, 2021
FY2020 Jun 30, 2020 ($56.00M) Apr 30, 2021
FY2020 Mar 31, 2020 ($208.30M) Apr 30, 2021
FY2020 Dec 31, 2019 ($33.90M) Apr 30, 2021

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.83B Feb 13, 2026
FY2025 Dec 31, 2024 $1.37B Feb 13, 2026
FY2025 Dec 31, 2023 $872.20M Feb 13, 2026
FY2024 Dec 31, 2022 $223.40M Feb 18, 2025
FY2023 Dec 31, 2021 $259.90M Feb 23, 2024
FY2022 Dec 31, 2020 $213.50M Feb 27, 2023
FY2021 Dec 31, 2019 $206.10M Mar 1, 2022

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $441.70M Feb 13, 2026
FY2025 Dec 31, 2024 $367.60M Feb 13, 2026
FY2025 Dec 31, 2023 $303.50M Feb 13, 2026
FY2024 Dec 31, 2022 $282.00M Feb 18, 2025
FY2023 Dec 31, 2021 $266.40M Feb 23, 2024
FY2022 Dec 31, 2020 $228.60M Feb 27, 2023
FY2021 Dec 31, 2019 $229.40M Mar 1, 2022
FY2020 Dec 31, 2018 $198.30M Apr 30, 2021

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.62B Feb 13, 2026
FY2025 Dec 31, 2024 $1.37B Feb 13, 2026
FY2025 Dec 31, 2023 $1.31B Feb 13, 2026
FY2024 Dec 31, 2022 $1.18B Feb 18, 2025
FY2023 Dec 31, 2021 $1.11B Feb 23, 2024
FY2020 Dec 31, 2020 $265.50M Apr 30, 2021
FY2020 Sep 30, 2020 $251.70M Apr 30, 2021
FY2020 Jun 30, 2020 $226.30M Apr 30, 2021
FY2020 Mar 31, 2020 $264.80M Apr 30, 2021
FY2020 Dec 31, 2019 $291.80M Apr 30, 2021

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.11B Feb 13, 2026
FY2025 Dec 31, 2024 $1.32B Feb 13, 2026
FY2025 Dec 31, 2023 $900.50M Feb 13, 2026
FY2024 Dec 31, 2022 ($152.80M) Feb 18, 2025
FY2023 Dec 31, 2021 $210.90M Feb 23, 2024
FY2022 Dec 31, 2020 $208.90M Feb 27, 2023
FY2021 Dec 31, 2019 $57.50M Mar 1, 2022
FY2020 Dec 31, 2018 ($221.90M) Apr 30, 2021
FY2018 Dec 31, 2016 ($25.0K) Mar 13, 2019

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $220.00M Feb 13, 2026
FY2025 Dec 31, 2024 $167.00M Feb 13, 2026
FY2025 Dec 31, 2023 $127.90M Feb 13, 2026
FY2024 Dec 31, 2022 $100.00M Feb 18, 2025
FY2023 Dec 31, 2021 $73.40M Feb 23, 2024
FY2022 Dec 31, 2020 $44.40M Feb 27, 2023
FY2021 Dec 31, 2019 $47.60M Mar 1, 2022
FY2020 Dec 31, 2018 $64.60M Apr 30, 2021

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $12.21B Feb 13, 2026
FY2025 Dec 31, 2024 $9.13B Feb 13, 2026
FY2024 Dec 31, 2023 $8.00B Feb 18, 2025
FY2023 Dec 31, 2022 $7.10B Feb 23, 2024
FY2022 Dec 31, 2021 $6.94B Feb 27, 2023
FY2021 Dec 31, 2020 $5.07B Mar 1, 2022
FY2020 Dec 31, 2019 $4.66B Apr 30, 2021
FY2019 Dec 31, 2018 $697.34M Mar 12, 2020
FY2018 Dec 31, 2017 $25.0K Mar 13, 2019

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $8.27B Feb 13, 2026
FY2025 Dec 31, 2024 $6.70B Feb 13, 2026
FY2024 Dec 31, 2023 $5.98B Feb 18, 2025
FY2023 Dec 31, 2022 $5.65B Feb 23, 2024
FY2022 Dec 31, 2021 $5.52B Feb 27, 2023
FY2021 Dec 31, 2020 $4.56B Mar 1, 2022
FY2020 Sep 30, 2020 $4.63B Apr 30, 2021
FY2020 Jun 30, 2020 $4.52B Apr 30, 2021
FY2020 Mar 31, 2020 $4.35B Apr 30, 2021
FY2020 Dec 31, 2019 $5.36B Apr 30, 2021

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $3.94B Feb 13, 2026
FY2025 Dec 31, 2024 $2.43B Feb 13, 2026
FY2025 Dec 31, 2023 $2.01B Feb 13, 2026
FY2025 Dec 31, 2022 $1.44B Feb 13, 2026
FY2024 Dec 31, 2021 $1.42B Feb 18, 2025
FY2023 Dec 31, 2020 $512.10M Feb 23, 2024
FY2020 Sep 30, 2020 $146.10M Apr 30, 2021
FY2020 Jun 30, 2020 $213.00M Apr 30, 2021
FY2020 Mar 31, 2020 $276.20M Apr 30, 2021
FY2022 Dec 31, 2019 ($704.80M) Feb 27, 2023

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.03B Feb 13, 2026
FY2025 Dec 31, 2024 $1.32B Feb 13, 2026
FY2025 Dec 31, 2023 $1.33B Feb 13, 2026
FY2024 Dec 31, 2022 $1.28B Feb 18, 2025
FY2023 Dec 31, 2021 $1.33B Feb 23, 2024
FY2022 Dec 31, 2020 $607.20M Feb 27, 2023
FY2021 Dec 31, 2019 $605.80M Mar 1, 2022
FY2020 Dec 31, 2018 $634.00M Apr 30, 2021

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.03B Feb 13, 2026
FY2025 Dec 31, 2024 ($238.30M) Feb 13, 2026
FY2024 Dec 31, 2023 ($691.90M) Feb 18, 2025
FY2023 Dec 31, 2022 ($1.14B) Feb 23, 2024
FY2022 Dec 31, 2021 ($1.22B) Feb 27, 2023
FY2021 Dec 31, 2020 ($1.33B) Mar 1, 2022
FY2020 Sep 30, 2020 ($1.37B) Apr 30, 2021
FY2020 Jun 30, 2020 ($1.26B) Apr 30, 2021
FY2020 Mar 31, 2020 ($1.21B) Apr 30, 2021
FY2020 Dec 31, 2019 ($1.00B) Apr 30, 2021

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.73B Feb 13, 2026
FY2025 Dec 31, 2024 $1.23B Feb 13, 2026
FY2025 Dec 31, 2023 $780.40M Feb 13, 2026
FY2024 Dec 31, 2022 $260.60M Feb 18, 2025
FY2023 Dec 31, 2021 $439.10M Feb 23, 2024
FY2022 Dec 31, 2020 $534.60M Feb 27, 2023
FY2021 Dec 31, 2019 $223.50M Mar 1, 2022
FY2020 Dec 31, 2018 $215.10M Apr 30, 2021

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.91B Feb 13, 2026
FY2025 Dec 31, 2024 $2.93B Feb 13, 2026
FY2024 Dec 31, 2023 $2.94B Feb 18, 2025
FY2023 Dec 31, 2022 $3.19B Feb 23, 2024
FY2022 Dec 31, 2021 $2.97B Feb 27, 2023
FY2021 Dec 31, 2020 $2.15B Mar 1, 2022
FY2020 Dec 31, 2019 $3.47B Apr 30, 2021

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 3 Feb 13, 2026
FY2025 Dec 31, 2024 1 Feb 13, 2026
FY2025 Dec 31, 2023 1 Feb 13, 2026
FY2024 Dec 31, 2022 0 Feb 18, 2025
FY2023 Dec 31, 2021 0 Feb 23, 2024
FY2020 Dec 31, 2020 0 Apr 30, 2021
FY2020 Sep 30, 2020 0 Apr 30, 2021
FY2020 Jun 30, 2020 0 Apr 30, 2021
FY2020 Mar 31, 2020 0 Apr 30, 2021
FY2021 Dec 31, 2019 (1) Mar 1, 2022

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 3 Feb 13, 2026
FY2025 Dec 31, 2024 1 Feb 13, 2026
FY2025 Dec 31, 2023 1 Feb 13, 2026
FY2024 Dec 31, 2022 0 Feb 18, 2025
FY2023 Dec 31, 2021 0 Feb 23, 2024
FY2020 Dec 31, 2020 0 Apr 30, 2021
FY2020 Sep 30, 2020 0 Apr 30, 2021
FY2020 Jun 30, 2020 0 Apr 30, 2021
FY2020 Mar 31, 2020 0 Apr 30, 2021
FY2021 Dec 31, 2019 (1) Mar 1, 2022

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 382.55M Feb 13, 2026
FY2025 Dec 31, 2024 380.70M Feb 13, 2026
FY2024 Dec 31, 2023 381.79M Feb 18, 2025
FY2023 Dec 31, 2022 377.37M Feb 23, 2024
FY2022 Dec 31, 2021 375.80M Feb 27, 2023
FY2021 Dec 31, 2020 342.02M Mar 1, 2022
FY2020 Dec 31, 2019 118.26M Apr 30, 2021